Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...

After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per ...